Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs

Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control

Volumn 105, Issue 6, 1997, Pages 430-437

  Ziemann, Ulf ^a   Tergau, Frithjof ^a   Bruns, Dirk ^a   Baudewig, Jürgen ^a   Paulus, Walter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Dopamine receptor agonists; Intracortical inhibition and facilitation; Motor cortex; Neuroleptics; Paired transcranial magnetic stimulation

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; DOPAMINE RECEPTOR AFFECTING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; SELEGILINE; SULPIRIDE;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MAGNETIC STIMULATION; MALE; MOTOR CORTEX; NERVE CELL EXCITABILITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; BROMOCRIPTINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; HALOPERIDOL; HUMANS; LEVODOPA; MAGNETICS; MALE; MOTOR CORTEX; PHYSICAL STIMULATION; REFERENCE VALUES; SELEGILINE; SULPIRIDE;

EID: 0031473478     PISSN: 0924980X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-980X(97)00050-7     Document Type: Article

References (56)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders (see comments). Trends Neurosci. 12:1989;366-375.
2. Ashby P., Lang A.E., Lozano A.M., Dostrovsky J.O. Motor effects of stimulating the human cerebellar thalamus. J. Physiol. (Lond.). 489:1995;287-298.
3. Barker A.T., Jalinous R., Freeston I.L. Non-invasive magnetic stimulation of human motor cortex (letter). Lancet. 1:1985;1106-1107.
4. Cepeda C., Radisavljevic Z., Peacock W., Levine M.S. Differential modulation by dopamine of responses evoked by excitatory amino acids in human cortex. Synapse, 11:1992;330-341.
5. Chen R., Samii A., Canos M., Wassermann E.M., Hallett M. Effects of phenytoin on cortical excitability in humans. Neurology, 49:1997;881-883.
6. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
7. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
8. Doudet D.J., Gross C., Arluison M., Bioulac B. Modifications of precentral cortex discharge and EMG activity in monkeys with MPTP-induced lesions of DA nigral neurons. Exp. Brain Res. 80:1990;177-188.
9. Ferris C.D., Hirsch D.J., Brooks B.P., Snyder S.H. Sigma receptors: from molecule to man. J. Neurochem. 57:1991;729-737.
10. Fuxe K., Hokfelt T., Agnati L., Johansson O., Ljungdahl A., Perez de la Mora M. Regulation of the mesocortical dopamine neurons. Adv. Biochem. Psychopharmacol. 16:1977;47-55.
11. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15:1992;133-139.
12. Goldman-Rakic P.S., Lidow M.S., Smiley J.F., Williams M.S. The anatomy of dopamine in monkey and human prefrontal cortex. J. Neural Transm. 36(Suppl.):1992;163-177.
13. Hanajima R., Ugawa Y., Terao Y., Ogata K., Kanazawa I. Ipsilateral corticocortical inhibition of the motor cortex in various neurological disorders. J. Neurol. Sci. 140:1996;109-116.
14. Harder S., Baas H., Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin. Pharmacokinet. 29:1995;243-256.
15. Hufnagel A., Elger C.E., Marx W., Ising A. Magnetic motor-evoked potentials in epilepsy: effects of the disease and of anticonvulsant medication. Ann. Neurol. 28:1990;680-686.
16. Inase M., Tanji J. Thalamic distribution of projection neurons to the primary motor cortex relative to afferent terminal fields from the globus pallidus in the macaque monkey. J. Comp. Neurol. 353:1995;415-426.
17. Kaneko K., Kawai S., Fuchigami Y., Morita H., Ofuji A. The effect of current direction induced by transcranial magnetic stimulation on the corticospinal excitability in human brain. Electroenceph. clin. Neurophysiol. 101:1996;478-482.
18. Krnjevic K., Phillis J.W. Actions of certain amines on cerebral cortical neurons. Br. J. Pharmacol. 20:1963;471-490.
19. Köhler C., Ogren S.O., Fuxe K. Studies on the mechanism of action of substituted benzamide drugs. Acta Psychiatr. Scand. 311(Suppl.):1984;125-137.
20. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., Wroe S., Asselman P., Marsden C.D. Corticocortical inhibition in human motor cortex. J. Physiol. (Lond.). 471:1993;501-519.
21. Marsden C.D., Obeso J.A. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain. 117:1994;877-897.
22. Matsumoto R.R., Hemstreet M.K., Lai N.L., Thurkauf A., De Costa B.R., Rice K.C., Hellewell S.B., Bowen W.D., Walker J.M. Drug specificity of pharmacological dystonia. Pharmacol. Biochem. Behav. 36:1990;151-155.
23. Mavroudakis N., Caroyer J.M., Brunko E., Zegers de Beyl D. Effects of diphenylhydantoin on motor potentials evoked with magnetic stimulation. Electroenceph. clin. Neurophysiol. 93:1994;428-433.
24. Mavroudakis N., Caroyer J.M., Brunko E., Zegers de Beyl D. Effects of vigabatrin on motor potentials with magnetic stimulation. Electroenceph. clin. Neurophysiol. 105:1997;124-127.
25. Montastruc J.L., Llau M.E., Rascol O., Senard J.M. Drug-induced parkinsonism: a review. Fundam. Clin. Pharmacol. 8:1994;293-306.
26. Mouradian M.M., Juncos J.L., Fabbrini G., Chase T.N. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann. Neurol. 22:1987;475-479.
27. Murray N.M. F The clinical usefulness of magnetic cortical stimulation (editorial). Electroenceph. clin. Neurophysiol. 85:1992;81-85.
28. Nakamura H., Kitagawa H., Kawaguchi Y., Tsuji H. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J. Physiol. (Lond.). 498:1997;817-823.
29. Nambu A., Yoshida S., Jinnai K. Projection on the motor cortex of thalamic neurons with pallidal input in the monkey. Exp. Brain Res. 71:1988;658-662.
30. Priori A., Berardelli A., Inghilleri M., Accornero N., Manfredi M. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. Brain. 117:1994;317-323.
31. Quinn N., Marsden C.D. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry. 47:1984;844-847.
32. Reader T.A., Ferron A., Descarries L., Jasper H.H. Modulatory role for biogenic amines in the cerebral cortex. Microiontophoretic studies. Brain Res. 160:1979;217-229.
33. Reutens D.C., Berkovic S.F., Macdonell R.A., Bladin P.F. Magnetic stimulation of the brain in generalized epilepsy: reversal of cortical hyperexcitability by anticonvulsants. Ann. Neurol. 34:1993;351-355.
34. Reutens D.C., Berkovic S.F. Increased cortical excitability in generalised epilepsy demonstrated with transcranial magnetic stimulation (letter). Lancet. 339:1992;362-363.
35. Ridding, M.C., Inzelberg, R. and Rothwell, J.C. Changes in excitability of motor cortical circuitry in patients with Parkinson's disease. Ann. Neurol., 1995a, 37: 181-188.
36. Ridding, M.C., Sheean, G., Rothwell, J.C., Inzelberg, R. and Kujirai, T. Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia. J. Neurol. Neurosurg. Psychiatry, 1995b, 59: 493-498.
37. Ridding, M.C., Taylor, J.L. and Rothwell, J.C. The effect of voluntary contraction on cortico-cortical inhibition in human motor cortex. J. Physiol. (Lond.), 1995c, 487: 541-548.
38. Ross R.T. Drug-induced parkinsonism and other movement disorders. Can. J. Neurol. Sci. 17:1990;155-162.
39. Rossini P.M., Barker A.T., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q.et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroenceph. clin. Neurophysiol. 91:1994;79-92.
40. Rothblat D.S., Schneider J.S. Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic, and recovered MPTP-treated cats. J. Neurosci. 13:1993;4372-4378.
41. Rothwell, J.C. The use of paired pulse stimulation to investigate the intrinsic circuitry of human motor cortex. In: J. Nilsson, M. Panizza and F. Grandori (Eds.), Advances in Magnetic Stimulation. Mathematical Modelling and Clinical Applications, PI-ME Press, Pavia, 1996: 99-104.
42. Rothwell J.C., Thompson P.D., Day B.L., Boyd S., Marsden C.D. Stimulation of the human motor cortex through the scalp. Exp. Physiol. 76:1991;159-200.
43. Schönle P.W., Isenberg C., Crozier T.A., Dressler D., Machetanz J., Conrad B. Changes of transcranially evoked motor responses in man by midazolam, a short acting benzodiazepine. Neurosci. Lett. 101:1989;321-324.
44. Smiley J.F., Williams S.M., Szigeti K., Goldman-Rakic P.S. Light and electron microscopic characterization of dopamine-immunoreactive axons in human cerebral cortex. J. Comp. Neurol. 321:1992;325-335.
45. Terao Y., Hayashi H., Shimizu T., Tanabe H., Hanajima R., Ugawa Y. Altered motor cortical excitability to magnetic stimulation in a patient with a lesion in globus pallidus. J. Neurol. Sci. 129:1995;175-178.
46. Walker J.M., Matsumoto R.R., Bowen W.D., Gans D.L., Jones K.D., Walker F.O. Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs. Neurology. 38:1988;961-965.
47. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6:1996;751-758.
48. Williams S.M., Goldman-Rakic P.S. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cereb. Cortex. 3:1993;199-222.
49. Ziemann, U., Bruns, D. and Paulus, W. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci. Lett., 1996a, 208: 187-190.
50. Ziemann, U., Bruns, D. and Paulus, W. Impaired motor cortex inhibition in patients with Parkinson's disease and other parkinsonian syndromes. A transcranial magnetic stimulation study (abstract). Mov. Disord., 1996b, 11(Suppl. 1): 72.
51. Ziemann, U., Bruns, D. and Paulus, W. Levodopa and dopamine agonists can enhance inhibition in the human motor cortex. Evidence from a transcranial magnetic stimulation study (abstract). Neurology, 1996c, 46: A342.
52. Ziemann U., Lönnecker S., Paulus W. Inhibition of human motor cortex by ethanol. A transcranial magnetic stimulation study. Brain. 118:1995;1437-1446.
53. Ziemann, U., Lönnecker, S., Steinhoff, B.J. and Paulus, W. The effect of lorazepam on the motor cortical excitability in man. Exp. Brain Res., 1996d, 109: 127-135.
54. Ziemann, U., Lönnecker, S., Steinhoff, B.J. and Paulus, W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann. Neurol., 1996e, 40: 367-378.
55. Ziemann U., Paulus W., Rothenberger A. Decreased motor inhibition in Tourette syndrome: Evidence from transcranial magnetic stimulation. Am. J. Psychiatry, 154:1997;1277-1284.
56. Ziemann, U., Rothwell, J.C. and Ridding, M.C. Interaction between intracortical inhibition and facilitation in human motor cortex. J. Physiol. (Lond.), 1996f, 496: 873-881.